Arbutus Biopharma heads into its August 19 earnings report with short sellers adding positions, the stock up on the week, and the lending market comfortably loose — a setup where the bearish thesis is growing in size but not yet in conviction.
Short interest is the clearest signal worth watching. It has climbed to 10.6% of the free float, up roughly 6% in a single week and 9% over the past month — a steady, deliberate rebuild rather than a sudden spike. The week's jump of just over one million shares was the sharpest single-session move in the 30-day window, landing on August 11 at approximately 20.3 million shares net short. That is a meaningful position for a small-cap biotech with a next catalyst just days away. Yet the borrow market tells a less aggressive story: availability is running near 453%, meaning there are roughly four-and-a-half shares available to borrow for every one already borrowed. Cost to borrow is just 0.57% — up 19% on the week, but still in territory that imposes no real friction on new shorts. The ORTEX short score is a steady 68, little changed across the past two weeks, suggesting the bears are accumulating without panic or urgency.
Options positioning adds nuance. The put/call ratio of 0.41 is almost exactly in line with its 20-day average of 0.40, producing a z-score barely above zero. For context, the same ratio was printing close to 0.19 in mid-July — a period of notably bullish call-heavy positioning — before drifting back toward neutral over the past three weeks. The options market, in other words, has repriced from outright bullish to flat. Call volume still dominates, but the edge has gone from pointed to merely present. The 52-week PCR range runs from 0.16 to 0.92, so at 0.41, the setup is neither defensive nor speculative — it is waiting.
The Street broadly agrees the stock is cheap relative to pipeline potential, but the data trails the story. The most recent analyst action on record (Chardan Capital maintaining a Buy at a $5 target, last updated November 2025) predates the current $4.67 price by several months, and the mean price target of $7.28 implies roughly 56% upside from here. That gap — a stock trading above the most-cited individual targets but below the mean — reflects a bifurcated coverage base. Jefferies holds the high-side target at $7 (raised in September 2024). Bulls point to imdusiran's clinical profile: faster HBV DNA suppression than standard therapy, combined with a 65% reduction in R&D expenses and quarterly revenue of $10.7 million versus $1.7 million a year earlier. Bears counter that patient recruitment competition is intensifying and that any stumble on clinical efficacy endpoints could reprice the stock sharply. The EPS surprise factor score of just 1 out of 100 underlines how consistently the company misses consensus — not unusual for clinical-stage biotechs, but a reminder that headline metrics often disappoint regardless of pipeline progress.
Institutional ownership adds one genuinely notable detail. Roivant Sciences holds 19.7% of shares, an anchor stake that has not moved. More active this quarter: Two Seas Capital added nearly 6 million shares to reach a 9.4% position, and Whitefort Capital added 2.5 million to reach 8%. BlackRock and State Street both added modestly in the most recent reporting period. The aggregate picture is of institutions using recent price weakness to build or add — a counterpoint to the short-seller accumulation happening simultaneously.
The next data point is the August 19 earnings release. Prior prints offer limited directional guidance: the May 14 announcement produced a 1-day decline of 1.6% followed by a 3% five-day recovery, while March-era releases were broadly flat to slightly positive. What to watch on the 19th is less whether revenue lines beat and more whether imdusiran data or licensing revenue updates give either the bulls or the 10%-short-interest bears a reason to move.
See the live data behind this article on ORTEX.
Open ABUS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
